dennis podlesak  domain associates portfolionewseventscontact aboutteaminitiatives team investment finance  operations dennis podlesak partner dennis joined domain as a partner in  and since joining the domain team has served as an active investor a company founder and as the chief executive officer or executive chairman for a number of portfolio investments resulting in multiple successful exits intial public offerings and new drug approvals to address unmet medical needs our deep tradition of partnering with entrepreneurs works because domain always has its eye on value value to patients partners entrepreneurs and investors that is why i enjoy being a part of the domain team because we truly can focus on creating companies that are of value to all involved in the process of developing innovative new technologies into impactful healthcare products most recently dennis led the growth and sale of tobira therapeutics to allergan plc in november   he previously served on the board of avanir pharmaceuticals through its acquistion by otsuka pharmaceuticals in january  and was a founding board member of rightcare solutions through its acquisiton by cardinal health in december   currently dennis is the chairman of the board at adynxx and syndax pharmaceuticals and a board member of dri holdings earlier in his tenure with domain dennis served as the chief executive officer of peninsula pharmaceuticals and after building the company led its sale to johnson  johnson in his next role dennis was a founder and the chief executive officer of cerexa and led its sale to forest laboratories dennis was also a founder and the chief executive officer of calixa therapeutics and successfully led the growth and subsequent sale of calixa to cubist pharmaceuticals dennis also served as executive chairman of corthera and after repositioning the company into the cardiovascular space led the sale of corthera to novartis ag prior to domain dennis served as senior vice president and head of the north american business unit for novartis ag and as a member of novartis pharmaceutical executive committee and global leadership team earlier in his career dennis served as vice president and head of the cec division of allergan inc and as member of allergans global and north american management teams dennis spent the first ten years of his career with smithkline beecham now glaxosmithkline plc dennis received a ba from western illinois university and an mba from pepperdine university and has completed postgraduate studies at the wharton school university of pennsylvania present investments adynxx ascenta therapeutics dri holdings syndax pharmaceuticals select past investments calixa therapeutics cerexa corthera peninsula pharmaceuticals regado biosciences rightcare solutions tobira therapeutics office princeton   contact assistant eileen galton news on dennis g podlesak news home advertising board and executive moves energy health care hedge funds m  a private equity technology person dennis g podlesak ▼ topic all topics ▼ organizations find news about organizations alumni find news on alumni of any org industries find news on a particular market your contacts find news on your contacts sign up for free daily alerts on this feed by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions follow change feed dennis g podlesak syndax pharmaceuticals adds biopharmaceutical industry leader keith a katkin to board of directors april    •  globenewswire  fast growing fully integrated biotech company with a market leading product said dennis podlesak chairman of syndax we welcome his addition to the board and  adynxx announces closing of series b financing january    •  pr newswire  therapeutic benefits of ayx and ready the compound for phase  said dennis podlesak chairman of the adynxx board of directors in addition we are  syndax adds global pharmaceutical business veteran to board of directors january    •  globenewswire  very pleased to welcome pierre legault to our board of directors said dennis podlesak chairman of syndax his broad global experience in drug development and  allergan to acquire tobira therapeutics expanding global gi rd pipeline and taking a leading rd position in nash september    •  pr newswire  and i look forward to the future success of this partnership added dennis podlesak chairman of the board of tobira under the terms of the  syndax raises  million in series c financingproceeds to fund further development of clinical stage candidate entinostat august    •  pr newswire  has endorsed our strategy to expand the scope of development for entinostat dennis podlesak chairman of syndax added the syndax team has rapidly advanced the  syndax appoints dr briggs w morrison as chief executive officer and michael a metzger as president and chief operating officer june    •  pr newswire  to have briggs and michael assume these critical executive roles said dennis g podlesak chairman of the syndax board of directors and partner at domain  tobira therapeutics forsakes ipo for m reverse merger regado biosciences rescued by deal  may    •  the deal pipeline  a reverse merger since september when ceo laurent fischer called regado chairman dennis podlesak expressing interest in theâ possibility of a deal according to peetz  tobira therapeutics completes financing and merger with regado biosciences newly nasdaqlisted tbra has approximately  million to complete nash phase b study and build multiindication platform with cenicriviroc may    •  pr newswire  board of directors of the combined company is comprised of nine representatives dennis podlesak chairman dr fischer carol brosgart md jeffrey cooper andrew fromkin patrick  reminder regado biosciences and tobira therapeutics merger agreement conference call set for  am est today jan  january    •  pr newswire  to be filed with the sec each of regados board of directors dennis podlesak jeff clark drew fromkin anton gopka pierre legault michael mendelsohn p  onetime ipo candidate tobira to merge with public regado bio january    •  san francisco business times  secondquarter  tobira ceo laurent fischer will lead the combined company and dennis podlesak current chairman of regardos board will be chairman tobira shareholders will  regado biosciences and tobira therapeutics announce merger agreement to create leading nash company closing cash balance of approximately  million provides financing through phase b nash program january    •  pr newswire  regado and the remaining six of whom will be designated by tobira dennis podlesak current chairman of regados board will be chairman of the board  top  phase iii disasters of  october    •  fiercebiotech  to look into strategic alternatives to optimize value for shareholders as chairman dennis podlesak put it the biotechs remaining assets are the phase i reg  regados ceo steps down as the biotech limps forward october    •  fiercebiotech  process of evaluating strategic alternatives to optimize value for shareholders as chairman dennis podlesak put it in a statement value has been hard to come  regado biosciences appoints michael a metzger ceo october    •  pr newswire  his many years of service and all his contributions to regado said dennis podlesak chairman of regados board of directors in addition we are very  regado biosciences appoints pharmaceutical business leader drew fromkin to board of directors june    •  pr newswire  we are delighted to welcome drew to our board of directors said dennis podlesak chairman of the board of regado biosciences drew brings a wealth  syndax announces appointment of richard p shea as independent director and chair of the audit committee january    •  pr newswire  experience joining our board at a critical time in syndaxs development said dennis podlesak chairman of syndaxs board of directors ricks experience will be indispensable  regado biosciences inc adds global pharmaceutical business veteran to board of directors november    •  pr newswire  success with reg i look forward to offering my expertise and guidance dennis podlesak mba regados board chairman stated we are very pleased to add  rightcare solutions raises m in series b round led by domain associates and compass partners november    •  business wire  both the continuum of care and outcomes for customers and patients said dennis podlesak partner at domain associates llc the rightcare team has shown tremendous  regado biosciences inc appoints worldrenowned leader in cardiovascular research and former global head of cardiovascular diseases for merck  co to board of directors november    •  pr newswire  the potential to improve bothefficacy and safety in patients undergoing these procedures dennis podlesak mba regados board chairman stated we are delighted to have dr  adynxx completes patient enrollment in phase  clinical study of lead therapeutic for prevention of pain ayx september    •  pr newswire  the study datain the next quarter and continuing to advance through development dennis podlesak chairman of the adynxx board of directors addedas evidenced by the  adynxx enrolls first patient in phase  proofofconcept study for ayx lead compound for the prevention of postsurgical pain february    •  pr newswire  with movement enabling patients to begin rehabilitation and resume other activities earlier dennis podlesak chairman of the adynxx board of directors added ayx is a  adynxx enrolls first patient in phase  proofofconcept study for ayx lead compound for the prevention of postsurgical pain february    •  pr newswire  with movement enabling patients to begin rehabilitation and resume other activities earlier dennis podlesak chairman of the adynxx board of directors added ayx is a  related news feeds domain associates llc private equity  venture capital board and executive moves in private equity  venture capital alumni of pepperdine university  graziadio school of business and management email linkedin facebook google tweet reddit permalink want to see the full history of news or view news on a particular date upgrade to relsci professional now start my free trial ➤ industry select a topic keyword go  ➤ find an organization select a topic keyword go  ➤ find a person select a topic keyword go  ➤ name of a school or name of an organization select a topic keyword go  ➤ thank you you are now subscribedplease wait for the page to refresh you are now subscribed to this feed you have unsubscribed to this feed thank you you can now subscribe to more relsci news feeds to subscribe to more than one feed please enter a password please confirm your password go  ➤ youve found a premium relsci pro feature follow news on your contacts upgrade to relsci pro now to easily sync your contacts and stay in the know on the news about the people important to you start my free trial ➤ still not convinced check out our full listing of features here not now youve found a premium relsci pro feature search news on keywords curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles start my free trial ➤ still not convinced check out our full listing of features here not now industries find news on a particular market people find news about people organizations find news about organizations alumni find news on alumni of any org your contacts find news on your contacts free daily alerts sign up for free daily alerts on this feed sign up ➤ by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions already have an account click here to login are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ dennis g podlesak mba executive profile  biography  bloomberg july    pm et capital markets company overview of domain associates llc snapshotpeople  overviewboard memberscommittees executive profile dennis g podlesak mbapartner domain associates llcagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr dennis g podlesak mba has been a partner at domain associates llc since february  mr podlesak joined domain associates in  and is an active investor and a founder of a number of domain companies he serves as chief executive officer or executive chairman for a number of domains companies resulting in multiple successful exits intial public offerings and new drug approvals to address unmet medical needs he served as the president and chief executive  officer of peninsula pharmaceuticals inc since september   and after building it he led the sale of it to johnson and johnson mr podlesak was a founder and the president and chief executive officer of cerexa inc and led the sale of cerexa to forest laboratories in his next role he was again a founder and the chief executive officer of calixa therapeutics inc and successfully led the growth and sale of calixa to cubist pharmaceuticals mr podlesak also served as the executive chairman of corthera and after repositioning the company actively participated in the sale of it to novartis ag previously he served at peninsula where he was a senior vice president and head of a north american business unit and global leadership team mr podlesak served in that capacity from february  to august  when that business unit was merged into another unit for strategic reasons he was recruited to novartis to strategically reposition and reengineer the north american business unit before this mr podlesak was a vice president and head of the cec division of allergan and member of the north american and global management team from july  to october  in that role he drove the revitalization and dramatic growth in revenue and profitability of the division and several of its leading brands mr podlesak was also a vice president and corporate officer at pcg prior to this role he spent the first  years of his career with smithkline beecham where mr podlesak was promoted eight times to positions of increasing responsibility during his tenure he serves as the chairman of adynxx he served as the chairman of the board at tobira therapeutics inc until november   and its director from december  to november   he has been the chairman of syndax pharmaceuticals inc since december  he served as the chairman of the board at corthera inc since january  he served as the chairman at regado biosciences inc since november  mr podlesak serves as a director of dri holdings calixa therapeutics inc and rightcare solutions inc he is a board observer at ascenta therapeutics and asmacure he served as a director of peninsula pharmaceuticals inc since september   until june  he served as an independent director of avanir pharmaceuticals inc from march   to january   he served as a director of cerexa inc he served as an independent director of dov pharmaceutical inc since april   mr podlesak is a board member of kalidex pharmaceuticals he is active on a number of industry boards and serves on the board of directors of prevent blindness mr podlesak has over  years of strategic operational and commercial experience within the pharmaceutical industry and a track record of success growing companies and leading business development and licensing financing and merger and acquisition initiatives mr podlesak earned an mba from pepperdine university in  completed post graduate studies from the wharton school university of pennsylvania and a ba degree in business administration from western illinois university in read full background corporate headquarters one palmer squareprinceton new jersey united statesphone fax  board members memberships chairmansyndax pharmaceuticals incdirectorcalixa therapeutics incdirectorrightcare solutions inc education mba pepperdine universityba western illinois universitymasters degree university of pennsylvania  the wharton school other affiliations avanir pharmaceuticals incdov pharmaceutical incpeninsula pharmaceuticals incpepperdine universitywestern illinois universityuniversity of pennsylvania  the wharton schoolregado biosciences inccorthera inccerexa incsyndax pharmaceuticals inctobira therapeutics inccalixa therapeutics incrightcare solutions inc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact domain associates llc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close dennis g podlesak  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in dennis g podlesak board member at syndax pharmaceuticals inc view full profile are you dennis g podlesak claim your profile   sign up for equilar atlas and view dennis g podlesaks full profile with equilar atlas you can identify corporate executives in dennis g podlesaks network and community follow changes in dennis g podlesaks employment and moneyinmotion connect with dennis g podlesak through your network of contacts dennis g podlesaks executive work history current board member syndax pharmaceuticals inc past to view dennis g podlesaks complete executive work history sign up now education ba western illinois university mba pepperdine university university of pennsylvania age      dennis g podlesaks biography mr podlesak is a class iii director who has served as chairman of our board of directors since december  since november  mr podlesak has served as a partner at domain associates llc a life sciencefocused venture capital firm while at domain mr podlesak has served as the chairman of the board of tobira therapeutics a publicly traded biopharmaceutical company that was acquired by allergan plc in november  mr podlesak also served on the board of avanir pharmaceuticals a publicly traded biopharmaceutical company through its acquisition by otsuka pharmaceuticals in january  and was on the board of rightcare solutions  read more mr podlesak is a class iii director who has served as chairman of our board of directors since december  since november  mr podlesak has served as a partner at domain associates llc a life sciencefocused venture capital firm while at domain mr podlesak has served as the chairman of the board of tobira therapeutics a publicly traded biopharmaceutical company that was acquired by allergan plc in november  mr podlesak also served on the board of avanir pharmaceuticals a publicly traded biopharmaceutical company through its acquisition by otsuka pharmaceuticals in january  and was on the board of rightcare solutions which was acquired by cardinal healths naviheath division in december  mr podlesak was also the founder and the chief executive officer of calixa therapeutics inc a privately held biopharmaceutical company that was acquired by cubist pharmaceuticals and mr podlesak was the executive chairman of corthera inc a privately held biopharmaceutical company which was acquired by novartis ag earlier in his career mr podlesak served as the founder and chief executive officer of cerexa inc a privately held biotechnology company which became a wholly owned subsidiary of forest laboratories inc after being acquired by forest prior to cerexa mr podlesak served as the chief executive officer of peninsula pharmaceuticals inc a privately held pharmaceutical company and led the sale of peninsula to johnson  johnsons orthomcneil pharmaceutical subsidiary prior to joining peninsula mr podlesak held various executive management positions at novartis ag a publicly traded healthcare company allergan plc a publicly traded healthcare company and smith kline beecham now glaxosmithkline plc a publicly traded pharmaceutical company mr podlesak is the chairman of adynxx and serves on other private company boards mr podlesak received a ba and an mba from pepperdine university and has completed postgraduate studies at the wharton school university of pennsylvania we believe that mr podlesaks experience in the venture capital industry his experience as the chief executive officer and chairman of other successful companies in the biotechnology industry his over  years of strategic operational and commercial experience in the pharmaceutical industry and his service as a director of other publicly traded and privately held life science companies give him the qualifications skills and financial expertise to serve on our board of directors source syndax pharmaceuticals inc on    sign up for equilar atlas and view dennis g podlesaks full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like dennis g podlesak more specifically youll be able to identify corporate executives in dennis g podlesaks network and community follow changes in dennis g podlesaks employment and moneyinmotion connect with dennis g podlesak through your network of conections view full profile   search for over  executive profiles bio example dennis g podlesak dennis g podlesaks connections  sign up now to view dennis g podlesaks  connections » scott m whitcup former executive vice president research and development and chief scientific officer allergan eckard weber former chairman of the board former interim president and chief executive officer orexigen therapeutics inc jesse i treu former board member tandem diabetes care inc zola p horovitz former board member palatin technologies inc james c blair former board member clovis oncology inc brian h dovey board member orexigen therapeutics inc brian k halak former board member alimera sciences inc paul g thomas chairman of the board roka bioscience inc eric k brandt chairman of the board yahoo inc r don elsey chief financial officer secretary and treasurer senseonics holdings inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla daniel a dematteo executive chairman gamestop corp david j oconnor president and ceo the madison square garden company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   dennis podlesak  domain associates llc  zoominfocom dennis podlesaks involvement in venture capital via regado biosciences inc syndax pharmaceuticals inc kalidex pharmaceuticals inc corthera inc adynxx inc rightcare solutions want to see morewant to find out who got funded and who’s funding the next big thing in real time all across the world tailored to your specific areas of focus deals per dayget access to the most exhaustive worldwide funding watch on the webcomprehensive funding informationknow about who invested in a company which sites covered the event the funding history etcexclusive insightsview original analytics such as most dynamic industries most active investors and morestay awareget emailed when deals critical to your business happen filter by region industry and topics of interestas seen onhave a loginsign inregister nowits freeuse your social accountor fill in the quick formregister nowpromise we wont spamsign invia your social accountvia your existing wgf accountremember meregister its freeforgot your passwordsign inforgot your passwordenter your email and we will send you your new passwordreset passwordthe worlds largest funding basepeopledennispodlesaksectionpeoplesubsectiondetailid search deals by company name industry location investors search dennispodlesakget alertedif dennis podlesak gets fundeddennis podlesakregado biosciences inc  board chairman director executiveofficersyndax pharmaceuticals inc  board chairman directorkalidex pharmaceuticals inc  director board membercorthera inc  director executive chairmanadynxx inc  director board chairmanrightcare solutions  director board of directorsdeals involving dennis podlesak raised with regado biosciences inc on august  raised with regado biosciences inc on december  raised with regado biosciences inc on may  raised with regado biosciences inc on july  raised with regado biosciences inc on december  raised with syndax pharmaceuticals inc on august  raised with syndax pharmaceuticals inc on august  raised with syndax pharmaceuticals inc on august  raised with syndax pharmaceuticals inc on february  raised with kalidex pharmaceuticals inc on march  raised with kalidex pharmaceuticals inc on november  raised with corthera inc on april  raised with adynxx inc on january  raised with adynxx inc on december  raised with adynxx inc on december  raised with adynxx inc on august  raised with rightcare solutions on september  raised with rightcare solutions on october  raised with rightcare solutions on october please note that all data is automatically extracted and errors can occurthe whogotfunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and completesome of the profile information was collected using the crunchbase api for more details on the profile please check dennis podlesak on crunchbaseinaccurate data help us improve whogotfunded post a comment   forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied dennis podlesak ceo cerexa inc a publisher of business information since         search business search executive   advanced search   sign in    hints profile of dennis podlesak   dennis podlesak   ceo  cerexa inc   dennis podlesak email  please login   company name  cerexa inc   company website  wwwcerexacom   company address   harbor bay pkwy alameda caunited states   dennis podlesak profile  ceo  cerexa inc   dennis podlesak biography  mr podlesak is the chief executive officer of cerexa cerexa was spun out of peninsula pharmaceuticals where mr podlesak was also the chief executive officer and where he led the sale of peninsula to johnson  johnson mr podlesak has over  years of strategic operational and commercial experience within the pharmaceutical industry prior to peninsula mr podlesak served as senior vice president and head of a north american business unit for novartis ag and as a member of novartis� pharmaceutical executive committee and global leadership team earlier in his career mr podlesak served as vice president and head of the cec division of allergan inc and as member of allergan�s north american and global management team mr podlesak spent the first ten years of his career with smithkline beecham now glaxosmithkline plc where he was promoted to eight positions of increasing responsibility during his tenure with the company mr podlesak serves on the board of directors of two publicly traded pharmaceutical companies avanir pharmaceuticals and dov pharmaceuticals and is a member of the board of directors of prevent blindness a non profit organization that focuses on preventable blindness with a particular emphasis on children mr podlesak holds a ba in business administration and an mba from pepperdine university   dennis podlesak colleagues  name title email dirk thye sr vice president� clinical development please login rick orr sr vp operations please login mary oharazimmerman sr vice president� regulatory quality please login james ge vice president� drug development please login ronald jones scientific advisor please login             home    about us    product information     subscription    list builder     executive list     email lists     contact us    site map    browse directory      �  walkerss research  a publisher of business information since  all rights reserved